Compare ARK Genomic Revolution ETF (ARKG) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Nasdaq Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Nasdaq Inc trades at $87.79 (market cap $49.81B). The key difference: Nasdaq Inc pays a 1.27% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Nasdaq Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | NDAQ | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $100.98 |
52-Week Low | $23.09 | $76.85 |
Market Cap | — | $49.81B |
Enterprise Value | — | $56.88B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Nasdaq (NDAQ) trades at $88.08, up 0.64% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. Revenue grew to $8.26 billion in 2025, with net income margin expanding to 23.03%. The stock shows robust institutional support, with 61% of analysts rating it a Buy and a consensus price target of $105.60, indicating ~20% upside potential.
Outlook remains positive given Nasdaq's dominant market position and exposure to capital markets growth, though risks include high valuation multiples (P/E 26.53) and sensitivity to equity market volatility. The stock's recent strength near resistance at $89 may prompt consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
